ly 353381 has been researched along with 4-[1-[4-[2-(dimethylamino)ethoxy]phenyl]-2-phenylbut-1-enyl]phenol in 1 studies
| Studies (ly 353381) | Trials (ly 353381) | Recent Studies (post-2010) (ly 353381) | Studies (4-[1-[4-[2-(dimethylamino)ethoxy]phenyl]-2-phenylbut-1-enyl]phenol) | Trials (4-[1-[4-[2-(dimethylamino)ethoxy]phenyl]-2-phenylbut-1-enyl]phenol) | Recent Studies (post-2010) (4-[1-[4-[2-(dimethylamino)ethoxy]phenyl]-2-phenylbut-1-enyl]phenol) |
|---|---|---|---|---|---|
| 70 | 12 | 15 | 76 | 0 | 32 |
| Protein | Taxonomy | ly 353381 (IC50) | 4-[1-[4-[2-(dimethylamino)ethoxy]phenyl]-2-phenylbut-1-enyl]phenol (IC50) |
|---|---|---|---|
| Phospholipase D2 | Homo sapiens (human) | 0.044 | |
| Steroid hormone receptor ERR2 | Homo sapiens (human) | 0.768 | |
| Estrogen receptor | Homo sapiens (human) | 0.4554 | |
| Progesterone receptor | Homo sapiens (human) | 0.0008 | |
| Androgen receptor | Rattus norvegicus (Norway rat) | 9.3325 | |
| Estrogen receptor | Mus musculus (house mouse) | 0.0332 | |
| Estrogen-related receptor gamma | Homo sapiens (human) | 0.3485 | |
| Estrogen-related receptor gamma | Mus musculus (house mouse) | 0.6 | |
| Platelet-activating factor acetylhydrolase | Homo sapiens (human) | 0.0005 | |
| Phospholipase D1 | Homo sapiens (human) | 4.8 | |
| Estrogen receptor beta | Homo sapiens (human) | 0.0527 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Aparicio, A; Bonnefous, C; Brigham, D; Darimont, B; Douglas, K; Govek, S; Grillot, K; Hager, JH; Heyman, R; Joseph, JD; Julien, J; Kahraman, M; Kaufman, J; Lai, A; Lee, KJ; Lu, N; Moon, MJ; Nagasawa, J; Prudente, R; Qian, J; Rix, PJ; Sensintaffar, J; Shao, G; Smith, ND | 1 |
1 other study(ies) available for ly 353381 and 4-[1-[4-[2-(dimethylamino)ethoxy]phenyl]-2-phenylbut-1-enyl]phenol
| Article | Year |
|---|---|
Identification of GDC-0810 (ARN-810), an Orally Bioavailable Selective Estrogen Receptor Degrader (SERD) that Demonstrates Robust Activity in Tamoxifen-Resistant Breast Cancer Xenografts.
Topics: Administration, Oral; Animals; Antineoplastic Agents; Breast; Breast Neoplasms; Cell Line, Tumor; Dogs; Drug Discovery; Drug Resistance, Neoplasm; Estrogen Receptor alpha; Female; Heterografts; Humans; Mice; Proteolysis; Rats; Selective Estrogen Receptor Modulators; Small Molecule Libraries; Tamoxifen | 2015 |